Eurydice Posted - 1 day ago

$VIRX LFG! Do something!

notfunny Posted - 04/30/24

$IBRX $VIRX Guys buy also Viracta Therapeutics the other company from the Patrick Soon Shiong ecosystem of Biotech companies. It may play a critical role in the future for IBRX approach of triangle offense

notfunny Posted - 04/29/24

$VIRX lets see if Viraxa therapeutic may play a role in combination with Anktiva of its parent company IBRX. IBRX just received BLA for Anktiva in combination with BCG. Perhaps BCG can be replaced by some viral, rather than bacterial, immunostimulans. given the run of IBRX and the news to come here i would stick in this one for a while. It can only go up in the long run and may climb up in the wind ahadow of IBRX.

bubblegumkid Posted - 04/29/24

$VIRX - when are we expecting news on this? Anyone know….

Eurydice Posted - 04/22/24

$VIRX 🦗 🦗 🦗

Eurydice Posted - 04/19/24

$VIRX losing patience. Have held shares too long. Thought it was ready to move until Monday.

Drerekcohert90 Posted - 04/17/24

$LCTX $VIRX $INVO $VNDA Number one in calling stocks! Money machine, this dude!

Stockchooser Posted - 04/17/24

$VIRX ⬆️⬆️⬆️ https://www.webullapp.com/news-detail/10594004729897984?theme=1&hl=en&color=2&_v=1&tickerId=913254157&disSymbol=VIRX&sp=0&hl=en

jacksparo Posted - 04/17/24

$VIRX Adding yesterday was a gift ✅✅✅ My super penny stock list 📈

Thestocktraderhubzee Posted - 04/17/24

$VIRX Oppenheimer Maintains Outperform on Viracta Therapeutics, Maintains $13 Price Target

Eurydice Posted - 04/17/24

@bubblegumkid it will probably crater to .45 again and bounce back to 1.0 with talk of FDA approval. Does not appear the street sees much value in $virx.

Eurydice Posted - 04/17/24

$VIRX Here they come. HC Wainright reiterates 4.00 price target. What the hell is the time period of these damn things? Anyone remember the $45 PT? Keep telling the story. The shareholders are the only ones holding the risk.

Fullratio Posted - 04/16/24

$VIRX total assets is 48% higher than its total liabilities: https://fullratio.com/stocks/nasdaq-virx/viracta-therapeutics

bubblegumkid Posted - 04/16/24

$VIRX argh I don’t know what to do with this anymore…

Happy_Feet19 Posted - 04/16/24

$VIRX What was the street expecting in ORR & CRR from our stage 1 study? We got 50% ORR & 20% CRR. Meeting w/ FDA 2Q2024 for AA in Mid-2024 Stage 2 results in 3Q24. Are we expecting better then stage 1?

SkyHighParaboilcTrader Posted - 04/15/24

$SNGX 0.70 if it holds over 1.00 $MOB 1.70+ $SBFM reverse split on Tuesday $YYAI 2.70+ can go over 3.00 $VIRX if it can hold up back over 1.00 good luck on Tuesday traders

Cimmtas Posted - 04/15/24

$VIRX

Stormra Posted - 04/15/24

$VIRX WHAT HAPPENED??

Eurydice Posted - 04/15/24

$VIRX let’s see. The usual game plan is for a few “analysts“ to reiterate their buy rating and give a price target after substantial drops like this It has been the longest 12 months ever.

BrexitIsStupid Posted - 04/15/24

$VIRX Gets positive news and share price drops.

Stormra Posted - 04/15/24

$VIRX April 15 (Reuters) - Viracta Therapeutics Inc (VIRX.NaE): * VIRACTA THERAPEUTICS ANNOUNCES POSITIVE TOPLINE NANA-VAL RESULTS FROM STAGE 1 OF THE NAVAL-1 TRIAL IN PATIENTS WITH RELAPSED OR REFRACTORY EPSTEIN-BARR VIRUS-POSITIVE (EBV+) PERIPHERAL T-CELL LYMPHOMA * VIRACTA: NANA-VAL DEMONSTRATED GREATER EFFICACY THAN NANATINOSTAT MONOTHERAPY AND WAS GENERALLY WELL-TOLERATED Source text for Eikon: Further company coverage:

Eurydice Posted - 04/15/24

$VIRX why are the words out of the company's figurative mouth always in direct contrast with the stock price!!

longterminvs Posted - 04/15/24

$VIRX Sold off this morning at $1.01. Overall loss, but moving to other names. The data wasn't a failure but it wasn't that good. This is from a Bio Analyst. "Meh data" Data in April 2024 >> 2-arms in r/r EBV+ PTCL: A) nana-val N=10 vs. B) nana-only N=10 (designed to show that Val has value in the regimen). The (A) cohort has already progressed to Stage-2, so this was just the Stage-1 preliminary look. N=10 Data: ORR: 50% (5 of 100), CRR: 20% (2 of 10), but they said that N=7 was the "Evaluable" population and there they got 71% (5 of 7) and 29% (2 of 7), so of course the data are better when you toss out 3 non-responders! In Arm-B (Nana only, N=8 Evaluable): ORR: 13%. Was really hoping for better numbers here.

Stmkr Posted - 04/15/24

$VIRX Why is down acter seemingly positive results?

Hiimbill Posted - 04/15/24

$VIRX signs of a rookie 👏🏽 What other genius predictions do you have for us, Nostradamus? 🤔 Remember folks, when you invest with your OWN money, it’s always best to do your own DD

INTS915 Posted - 04/15/24

$VIRX piece of junk.

Eurydice Posted - 04/15/24

$VIRX once again 🖕Viracta

DonCorleone77 Posted - 04/15/24

$VIRX Viracta Therapeutics announces Nana-val results from stage 1 NAVAL-1 trial Viracta Therapeutics reported positive topline results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial from both arms of the relapsed or refractory Epstein-Barr virus-positive peripheral T-cell lymphoma cohort. These data were featured in an oral presentation during the 2024 Joint Annual Congress of Taiwan Society of Blood and Marrow Transplantation and The Hematology Society of Taiwan. Key takeaways from the pivotal Phase 2 NAVAL-1 trial in patients with R/R EBV+ PTCL: Nana-val demonstrated greater efficacy than nanatinostat monotherapy and was generally well-tolerated. The median duration of response continues to mature. Overview: A total of 20 patients with primarily Stage III-IV disease were randomized to receive nanatinostat alone or as Nana-val in combination with valganciclovir. Patients who did not respond to nanatinostat monotherapy after 6 weeks of treatment were offered the opportunity to cross over to receive Nana-val. Efficacy was evaluated as of the February 7, 2024 data cutoff date. In the Nana-val arm, the overall response rate was 50% and the complete response rate was 20% in the intent-to-treat population; the ORR was 71% and the CRR was 29% in the efficacy-evaluable population. In the nanatinostat monotherapy arm, the ORR and CRR were 10% and 0%, respectively, in the ITT population, and the ORR was 13% in the efficacy-evaluable population. Five nanatinostat monotherapy patients crossed over to receive Nana-val, two of whom remain on Nana-val treatment with stable disease as of the data cutoff. Safety was also evaluated as of the February 7, 2024 data cutoff date. The most common treatment-related adverse events in both treatment arms were thrombocytopenia, anemia, fatigue, decreased appetite, nausea, diarrhea, and weight loss. These adverse events were primarily mild to moderate in severity and generally manageable or reversible.

INTS915 Posted - 04/15/24

$VIRX scam alerts ⚠️

TheTradeXchange Posted - 04/15/24

$VIRX - Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma